Cerus Corp (NASDAQ:CERS)

CAPS Rating: 2 out of 5

The Company develops and commercializes novel, proprietary products and technologies within the fields of blood safety and immunotherapy that provides safer and more medical options to patients in areas of unmet medical need.

Recs

4
Player Avatar mansloth (98.74) Submitted: 8/22/2006 9:02:15 PM : Outperform Start Price: $5.40 CERS Score: -55.22

This is probably the riskiest pick in my CAPS portfolio, and I would strongly caution against picking this for yourself.

I'm picking this becauase I believe thier strategy with CRS-100 is likely to go all the way. Their blood safety system should provide modest revenues in the short term, but I'm banking that they will get a partner for CRS-100 in the next 2-4 years and eventually develop more Listeria-based therapies.

Member Avatar moneymog (< 20) Submitted: 11/16/2012 8:15:23 PM
Recs: 0

7 years of the ups and downs of CERS and I have had great reward. The crux was that the last FDA review for the submittal of a Phase Three Trial Outline was failed by just one vote on a sixteen member panel. THAT is what has set Cerus back by over two years and prompted an additional release of stock/warrants at $2.85 when the stock was already over $3. Today the stock revisited that $2.85 number. Look at it this way... they can "purify" HIV, HN1 and denge fever. No doubt this set of patents can be tweeked to cure the living dead, no joke. Phase III red blood cell is very close in Europe/France especially, which no doubt, has booted the FDA into 'accelerating' the approval process for platelets, plasma, and red blood cell systems. No one can know clearly when such a powerful blood application will pop to the top of the chart.. buy now and hold long is the strategy with which I have stuck.... works for me.

Featured Broker Partners


Advertisement